Aptevo raises $4.5M via warrant exercises and private placement
Biotech firm Aptevo secures $4.5 million through warrant conversions and a private funding round, bolstering its cash position for R&D and operations.
Biotechnology company Aptevo Therapeutics Inc. announced it has raised $4.5 million through the exercise of outstanding warrants and a private placement.
The company said existing warrant holders converted securities into 2.5 million shares at $1.80 per share, generating $4.5 million in gross proceeds. Separately, Aptevo completed a private placement of 1.3 million shares at the same price, also raising $2.34 million.
Proceeds from both transactions will be used to fund research and development programs, clinical trials, and general corporate purposes, the company stated. Aptevo did not disclose the identities of private placement investors.
Aptevo, which focuses on developing immunotherapies for cancer and other diseases, has not provided further details on the allocation of funds beyond its stated priorities. The company’s shares were not listed on a major exchange as of the filing, and trading activity, if any, would occur over the counter.
The biotech firm has faced financial constraints in recent years, relying on such capital-raising measures to sustain operations while advancing its pipeline of experimental treatments.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →